Eligibility criteria sit at the center of every clinical trial.
They define who can participate, shape safety parameters, influence statistical power, and signal scientific intent. They also quietly determine how difficult enrollment will be and how representative the study population becomes.
For years, eligibility criteria have been built largely on precedent, clinical caution, and competitive positioning. Today, sponsors have the ability to test those criteria against real-world populations before a protocol is finalized.
That shift is changing how feasibility is defined.
The Gap Between Protocol and Practice
In routine clinical care, patients are complex. They present with multiple comorbidities, variable adherence histories, and diverse treatment pathways. They switch therapies for practical reasons. They may not follow idealized sequences of care.
Protocols, by contrast, often describe narrower populations. Exclusions may remove patients with common chronic conditions. Washout periods may extend longer than typical switching behavior. Prior therapy requirements may not align with actual treatment patterns.
Each criterion may have clinical justification. The combined effect can shrink the eligible population dramatically.
When draft eligibility criteria are applied to large claims or electronic health record datasets, sponsors often discover that a meaningful percentage of real-world patients would be excluded. In some therapeutic areas, common comorbidities account for a substantial portion of exclusion decisions. Treatment history requirements may eliminate patients who would otherwise reflect routine clinical use.
These findings are not theoretical. They translate directly into screen failures, extended enrollment timelines, and budget pressure.
Simulating Before You Launch
Pressure-testing eligibility criteria involves applying draft inclusion and exclusion rules to real-world datasets to simulate who would qualify.
Pharmacy claims can illuminate treatment histories and switching intervals. Medical claims can reveal the prevalence of comorbidities that may be unnecessarily restrictive. Longitudinal datasets can estimate how many patients meet all criteria within specific geographic regions.
This type of simulation allows teams to quantify trade-offs.
If expanding an upper age limit increases the eligible pool by a measurable percentage without introducing safety concerns, that becomes a strategic decision rather than a guess. If shortening a washout period aligns more closely with real-world practice and meaningfully improves feasibility, teams can evaluate that option early.
Pressure-testing does not dictate the answer. It informs the conversation.
Representation Begins Here
Underrepresentation is often discussed in the context of recruitment tactics. In reality, many representation challenges originate in eligibility design.
If criteria disproportionately exclude populations with higher comorbidity burden or variable treatment histories, downstream outreach efforts face structural limits. If eligibility aligns poorly with where and how patients receive care, site placement strategies become less effective.
Real-world simulations can highlight demographic and geographic patterns within the eligible pool. Sponsors can assess whether draft criteria disproportionately impact certain age groups, racial and ethnic populations, or socioeconomic segments.
When these patterns are visible before protocol lock, teams can adjust design decisions with intention rather than reacting to enrollment shortfalls later.
Balancing Rigor With Realism
Eligibility criteria exist for important reasons. Patient safety and scientific integrity cannot be compromised. The goal of pressure-testing is not to loosen standards indiscriminately. It is to ensure that each exclusion is purposeful and proportionate.
Cross-functional dialogue is critical. Clinical leaders, statisticians, regulatory experts, operational teams, and patient engagement specialists each bring valuable perspective. Real-world data provides a shared evidence base for these discussions.
When teams see how criteria perform against actual patient populations, assumptions become measurable. Decisions become more transparent. Trade-offs become clearer.
Reducing Amendments and Rescue Efforts
One of the most expensive moments in a clinical trial is the mid-study amendment.
Eligibility amendments are common drivers of delay. Expanding criteria after enrollment stalls may recover timelines, but it often requires regulatory submissions, site retraining, and budget adjustments.
Pressure-testing eligibility early reduces the likelihood of these reactive changes. It supports more realistic enrollment projections and more stable protocol execution.
Sponsors who adopt this approach often report fewer screen failures, improved enrollment predictability, and stronger alignment between study populations and real-world use.
A More Grounded Feasibility Model
Feasibility is evolving from a survey-based estimate to a data-informed discipline.
Site questionnaires and historical benchmarks remain important, but they are strengthened when paired with quantitative simulations. Together, they provide a fuller picture of what is operationally achievable.
Eligibility criteria will always require thoughtful clinical judgment. Real-world data does not replace expertise. It enhances it.
When protocols are pressure-tested against reality before they are finalized, studies are better positioned to enroll efficiently, reflect intended treatment populations, and deliver results that stand up to scrutiny.
Better alignment at the eligibility stage creates ripple effects across the entire trial lifecycle.
Continue the Conversation at SCOPE X
If you are exploring how real-world data and AI can strengthen feasibility planning and reduce enrollment risk, join the discussion at SCOPE X, a focused event dedicated to AI innovation in clinical trials.
SCOPE X brings together sponsors, data leaders, and clinical teams to examine practical applications of AI in eligibility modeling, recruitment strategy, and responsible data integration.